Research publications

Alfred Health research outcomes are published in a wide range of peer reviewed journals. 

Search or browse research publications by year, research area, publication type or keyword.

Clear filter
Publication Details
Cytomegalovirus in pregnancy: to screen or not to screen

Walker SP, Palma-Dias R, Wood EM, Shekleton P, Giles ML

(2013), BMC Pregnancy Childbirth, 13, 96

Improving the transition of highly complex patients into the community: impact of a pharmacist in an allogeneic stem cell transplant (SCT) outpatient clinic

Chieng R, Coutsouvelis J, Poole S, Dooley MJ, Booth D, Wei A

(2013), Support Care Cancer, 21(12), 3491-5

Discovery of potent and selective benzothiazole hydrazone inhibitors of Bcl-XL

Sleebs BE, Kersten WJ, Kulasegaram S, Nikolakopoulos G, Hatzis E, Moss RM, Parisot JP, Yang H, Czabotar PE, Fairlie WD, Lee EF, Adams JM, Chen L, van Delft MF, Lowes KN, Wei A, Huang DC, Colman PM, Street IP, Baell JB, Watson K, Lessene G

(2013), J Med Chem, 56(13), 5514-40

Targeting acute myeloid leukemia by dual inhibition of PI3K signaling and Cdk9-mediated Mcl-1 transcription

Thomas D, Powell JA, Vergez F, Segal DH, Nguyen NY, Baker A, Teh TC, Barry EF, Sarry JE, Lee EM, Nero TL, Jabbour AM, Pomilio G, Green BD, Manenti S, Glaser SP, Parker MW, Lopez AF, Ekert PG, Lock RB, Huang DC, Nilsson SK, Récher C, Wei AH, Guthridge MA

(2013), Blood, 122(5), 738-48

Utility of a clinical risk score to identify high-risk patients with de novo acute myeloid leukaemia in first remission after high-dose cytarabine (HiDAC) based induction chemotherapy

Ling V, Burnett AK, Bradstock K, Seymour JF, Hills RK, Wei A

(2013), Br J Haematol, 160(6), 861-3

Methylation of KLF5 contributes to reduced expression in acute myeloid leukaemia and is associated with poor overall survival

Diakiw SM, Perugini M, Kok CH, Engler GA, Cummings N, To LB, Wei AH, Lewis ID, Brown AL, D'Andrea RJ

(2013), Br J Haematol, 161(6), 884-8

Protein kinase activity of phosphoinositide 3-kinase regulates cytokine-dependent cell survival

Thomas D, Powell JA, Green BD, Barry EF, Ma Y, Woodcock J, Fitter S, Zannettino AC, Pitson SM, Hughes TP, Lopez AF, Shepherd PR, Wei AH, Ekert PG, Guthridge MA

(2013), PLoS Biol, 11(3), e1001515

Stage I of a phase 2 study assessing the efficacy, safety, and tolerability of barasertib (AZD1152) versus low-dose cytosine arabinoside in elderly patients with acute myeloid leukemia

Kantarjian HM, Martinelli G, Jabbour EJ, Quintás-Cardama A, Ando K, Bay JO, Wei A, Gröpper S, Papayannidis C, Owen K, Pike L, Schmitt N, Stockman PK, Giagounidis A; SPARK-AML1 Investigators

(2013), Cancer, 19(14), 2611-9

Fli-1 overexpression in hematopoietic progenitors deregulates T cell development and induces pre-T cell lymphoblastic leukaemia/lymphoma

Smeets MF, Chan AC, Dagger S, Bradley CK, Wei A, Izon DJ

(2013), PLoS One, 8(5), e62346

Modulating T regulatory cells in cancer: how close are we?

Banerjee A, Vasanthakumar A, Grigoriadis G

(2013), Immunol Cell Biol, 91(5), 340-9

Thymic regulatory T cell development: role of signalling pathways and transcription factors

Engel M, Sidwell T, Vasanthakumar A, Grigoriadis G, Banerjee A

(2013), Clin Dev Immunol, 2013, 617595

Tranexamic acid without prophylactic factor replacement for prevention of bleeding in hereditary bleeding disorder patients undergoing endoscopy: a pilot study

Davis A, Walsh M, McCarthy P, Brown G, Roberts S, Tran H, Street A, Fong CY, Kemp W

(2013), Haemophilia, 19(4), 583-9

Prevalence of transfusion-acquired hepatitis C in an Australian bleeding disorder population

Northcott MJ, Ong WL, Walsh M, McCarthy P, Belleli D, Tran H, Street A, Kemp W, Davis AK

(2013), Haemophilia, 19(6), 847-52

Central nervous system multiple myeloma--potential roles for intrathecal therapy and measurement of cerebrospinal fluid light chains

Lee D, Kalff A, Low M, Gangatharan S, Ho P, Bajel A, Ritchie D, Grigg A, Spencer A

(2013), Br J Haematol, 162(3), 371-5

Tissue-type plasminogen activator is an extracellular mediator of Purkinje cell damage and altered gait

Cops EJ, Sashindranath M, Daglas M, Short KM, da Fonseca Pereira C, Pang TY, Lijnen RH, Smyth IM, Hannan AJ, Samson AL, Medcalf RL

(2013), Exp Neurol, 249, 8-19

Limitations of targeted therapy with sorafenib in elderly high-risk myelodysplastic syndrome and acute myeloid leukemia

Wei A, Tan P

(2013), Leuk Lymphoma, 54(4), 675-6

GADD45A methylation predicts poor overall survival in acute myeloid leukemia and is associated with IDH1/2 and DNMT3A mutations

Perugini M, Iarossi DG, Kok CH, Cummings N, Diakiw SM, Brown AL, Danner S, Bardy P, Bik To L, Wei AH, Lewis ID, D'Andrea RJ

(2013), Leukemia, 27(7), 1588-92

High-dose cytarabine (24 g/m2) in combination with idarubicin (HiDAC-3) results in high first-cycle response with limited gastrointestinal toxicity in adult acute myeloid leukaemia

Low M, Lee D, Coutsouvelis J, Patil S, Opat S, Walker P, Schwarer A, Salem H, Avery S, Spencer A, Wei A

(2013), Intern Med J, 43(3), 294-7

Fludarabine, cytarabine, granulocyte-colony stimulating factor and amsacrine: an effective salvage therapy option for acute myeloid leukemia at first relapse

Fong CY, Grigoriadis G, Hocking J, Coutsouvelis J, Muirhead J, Campbell P, Paul E, Walker P, Avery S, Patil S, Spencer A, Schwarer A, Wei A

(2013), Leuk Lymphoma, 54(2), 336-41

Effectiveness of a single fixed dose of rasburicase 3 mg in the management of tumour lysis syndrome

Coutsouvelis J, Wiseman M, Hui L, Poole S, Dooley M, Patil S, Avery S, Wei A, Spencer A

(2013), Br J Clin Pharmacol, 75(2), 550-3

32 33 34 35 36